IOVA: Iovance Net earnings per share (EPS TTM)

Iovance Biotherapeutics, Inc. (IOVA) - corporate logo

Iovance Biotherapeutics (IOVA) TTM EPS dynamics visualize the business's financial stability, where the -0.52 metric reflects current trends. Robotic systems automate lymphocyte cultivation, eliminating human error. A strong team of immunotherapy experts drives scientific progress in state-of-the-art laboratories. Meanwhile, innovative melanoma treatment is entering the commercial scaling stage, unlocking new opportunities in the oncology market.

IOVA Iovance Biotherapeutics Net earnings per share for the last 12 months (07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for Iovance Corp (IOVA)

Fundamental valuation:IOVA - Iovance Corp
Flagship merchandise of Iovance

The investment attractiveness of Iovance Biotherapeutics (IOVA) depends on its ability to scale the complex synthesis of cell therapies under strict regulatory oversight. This metric calculates the final profit allocated per share per year, allowing for an assessment of the real return on equity considering production risks. An analysis of the current annual net income per share reveals the business's fundamental resilience to operating expenses.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Immatics NV (IMTX)|Net earnings per share for the last 12 months Xencor Corp XNCR|Compass Therapeutics Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Inc. REPL|LYEL - Earnings per share for the last twelve months|IPHA (innate-pharma.com) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen Ltd. (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)